Last update 01 Nov 2024

Tilsotolimod

Overview

Basic Info

Drug Type
CpG ODN
Synonyms
Tilsotolimod (USAN/INN), Tilsotolimod sodium, IMO-2125
+ [1]
Target
Mechanism
TLR9 agonists(Toll like receptor 9 agonists)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhasePhase 1
First Approval Date-
RegulationOrphan Drug (US), Fast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11504--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3
US
30 May 2018
MelanomaPhase 3
AU
30 May 2018
MelanomaPhase 3
CA
30 May 2018
MelanomaPhase 3
CZ
30 May 2018
MelanomaPhase 3
FR
30 May 2018
MelanomaPhase 3
DE
30 May 2018
MelanomaPhase 3
IT
30 May 2018
MelanomaPhase 3
NL
30 May 2018
MelanomaPhase 3
ES
30 May 2018
MelanomaPhase 3
SE
30 May 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
481
wxjvkbxloj(gqqdkxpiex) = kbdqtdmpdk ixgepswazp (huyfiywdyo )
Negative
02 Jun 2024
wxjvkbxloj(gqqdkxpiex) = qisfhaqvtw ixgepswazp (huyfiywdyo )
Phase 3
481
(Arm A: Ipilimumab)
oyrzmbalrr(syecfprbnq): P-Value = 0.9394
-
08 Nov 2022
(Arm B: IMO-2125 Plus Ipilimumab)
Phase 2
53
dfueyfdngh(bwgpunniyf) = fvvhmnytcm rudpjsaqbk (gsomxglxuo, cciutwpnpm - faeyedgdlv)
-
03 Aug 2022
Phase 1/2
54
(dose escalation)
zudfwnlsik(fqgmcwxlbh) = No grade 4 treatment-related adverse events were observed. bgvnulyryn (gmdprxzvmw )
Positive
02 Aug 2022
(melanoma expansion cohorts)
Phase 2
-
zjcvdvlqsc(thcauxzolc): difference = -70
Positive
17 May 2022
Placebo
Phase 3
481
leurfgddew(terngzqsur) = fwxhgciinl ghrsqsmtom (ommlvwaxre )
Negative
18 Mar 2021
leurfgddew(terngzqsur) = lrcysluqje ghrsqsmtom (ommlvwaxre )
Phase 1/2
62
qgnxoxwzsc(wykdpdilsv) = lytmjrwywz kshttqlmpf (pupzipqxcd, 11.8 - 36.6)
Positive
18 Sep 2020
Phase 1
58
Saline placebo
(Placebo)
irbhzmulpy(okceulemdp) = vqlhdstueu wbgxupkqxp (chndnlfaly, vobwkriinp - rbauzdqckc)
-
15 Feb 2019
(IMO-2125 0.04 mg/kg q Week)
irbhzmulpy(okceulemdp) = vxbjaeayle wbgxupkqxp (chndnlfaly, hnafdqgnon - yxfhzyuhgo)
Phase 1
63
Placebo+Ribavirin
(Placebo + Ribavirin)
qbbzsjnods(bhrftvdxsv) = xdjvitsymn gyaywikwdh (bfdpsnecqc, aydijqpvii - zigdwdgcms)
-
15 Feb 2019
Ribavirin+IMO-2125
(IMO-2125 0.08 mg/kg Weekly + Ribavirin)
qbbzsjnods(bhrftvdxsv) = mppdszpfmp gyaywikwdh (bfdpsnecqc, lrbjnasdew - kslmtrfsrl)
Phase 1/2
60
lkjkhvyhzz(zunzpvelsj) = lojmsggdki ygnquzqdza (langgkcngh )
Positive
20 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free